Rapport Therapeutics (NASDAQ:RAPP – Get Free Report)’s share price shot up 7% during trading on Friday . The stock traded as high as $19.80 and last traded at $19.62. 26,674 shares were traded during trading, a decline of 85% from the average session volume of 183,322 shares. The stock had previously closed at $18.34.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on RAPP. Jefferies Financial Group initiated coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price target on the stock. Stifel Nicolaus initiated coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 target price on the stock. Finally, TD Cowen initiated coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating on the stock.
Check Out Our Latest Report on Rapport Therapeutics
Rapport Therapeutics Price Performance
Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($1.02). On average, analysts expect that Rapport Therapeutics will post -3.46 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Rapport Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new stake in Rapport Therapeutics in the third quarter worth about $101,000. Sandia Investment Management LP acquired a new stake in Rapport Therapeutics in the second quarter worth about $116,000. Davidson Kempner Capital Management LP acquired a new stake in Rapport Therapeutics in the second quarter worth about $229,000. Squarepoint Ops LLC acquired a new stake in Rapport Therapeutics in the second quarter worth about $380,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Rapport Therapeutics in the second quarter worth about $1,757,000.
Rapport Therapeutics Company Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
See Also
- Five stocks we like better than Rapport Therapeutics
- What is a Bond Market Holiday? How to Invest and Trade
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- Using the MarketBeat Dividend Yield Calculator
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.